Abstract
Hepcidin has been proposed as an important factor in the pathogenesis of the anaemia of chronic disease (ACD). The aim of this study was to assess the relationship between anaemia and inflammatory activity in patients with solid tumours. Patients were classified as having iron deficiency anaemia (IDA) (hypoferremia and hypoferretinemia), ACD (hypoferremia, normal or increased serum ferritin) and anaemia related to cancer (ARC) (no abnormalities in iron status). Serum pro-hepcidin, IL-6, C-reactive protein (CRP) and iron status parameters were measured using commercial kits. CRP and IL-6 levels were significantly higher in patients with ACD when compared to IDA, ARC and non anaemic patients (P < 0.005). Serum pro-hepcidin levels were not different among all studied groups (P = 0.138). A negative correlation was observed between haemoglobin and serum ferritin, CRP and IL-6 levels only in group of ACD. Serum pro-hepcidin concentrations were not correlated with degree of anaemia or iron metabolism parameters. According to our results the inflammatory activity represented by high levels of IL-6 and CRP are involved in the pathogenesis of ACD, probably due to the action of inflammation on iron metabolism, but not in ARC. It was not possible to demonstrate a significant effect of pro-hepcidin on the anaemia in cancer patients.
Similar content being viewed by others
References
Harrison L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28:54–9.
Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25:2–6.
Weiss G, Goodnough LT. Medical progress: anemia of chronic disease. N Engl J Med 2005;352:1011–23.
Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol 2005;27:1–13.
Nemeth E, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone Hepcidin. J Clin Invest 2004;113:1271–6.
Macciò A, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005;106:362–7.
Ganz T. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171–82.
Means RT Jr. Hepcidin and anaemia. Blood Rev 2004;18:219–25.
Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2701–4.
Hinzmann R. Iron metabolism, iron deficiency and anaemia. Sysmex J Internat 2003;13:65–74.
Theurl I, et al. Dysregulated monocytes iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006;107:4142–8.
Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23.
Sweeney PJ, et al. Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomised, open-labelled, phase II trials. Br J Cancer 1998;77:1996–2002.
Bokemeyer C, Foubert J. Anemia impact and management: focus on patients needs and the use of erythropoietic agents. Semin Oncol 2004;31:4–11.
Noronha JFA, Grotto HZW. Measurement of reticulocyte and red blood cell indices in patients with iron deficiency and β-thalassemia minor. Clin Chem Lab Med 2005;43:195–7.
Fuchs D, Zangerle R, Denz H, Wachter H. Inhibitory cytokines in patients with anemia of chronic disorders. Ann NY Acad Sci 1994;718:344–6.
Jelkmann W. Proinflammatory cytokins lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–559.
Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002;99:3505–16.
Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.
Nemeth E, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–3.
Détivaud L, et al. Hepcidin levels in human are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746–8.
Kulaksiz H, et al. Pro-hepcidin: expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735–43.
Dallalio G, Fleury T, Means RT Jr. Serum Hepcidin in clinical specimens. Br J Haematol 2003;122:996–1000.
Brookes MJ, Sharma NK, Tselepis C, Iqbal TH. Serum pro-hepcidin: measuring active Hepcidin or a non-functional precursor? Gut 2005;54:169–70.
Acknowledgements
We are grateful to Prof. Maria Heloisa S L Blotta for offering the use of her laboratory, to Ms Carmem A C Aguiar and Ms Laurione C de Oliveira for technical assistance, and to Ms. Andrea Semolini for statistical analyses. Grant Sponsors: FAPESP, n° 08733-8/2004 and FAEP/UNICAMP no 369/04.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jacober, M.L.V., Mamoni, R.L., Lima, C.S.P. et al. Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia. Med Oncol 24, 323–329 (2007). https://doi.org/10.1007/s12032-007-0009-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-007-0009-9